肿瘤标志物CA15.3、CEA、CA-125和CA19.9在癌症转移中的应用

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2020-12-01 DOI:10.2217/bmt-2020-0015

G. Gaughran, N. Aggarwal, B. Shadbolt, R. Stuart-Harris

{"title":"肿瘤标志物CA15.3、CEA、CA-125和CA19.9在癌症转移中的应用","authors":"G. Gaughran, N. Aggarwal, B. Shadbolt, R. Stuart-Harris","doi":"10.2217/bmt-2020-0015","DOIUrl":null,"url":null,"abstract":"Background: Cancer antigen 15.3 (CA15.3) is a commonly used tumor marker (TM) in metastatic breast cancer (MBC) but may not be raised. We assessed CA15.3, carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125) and cancer antigen 19.9 in 193 MBC patients at diagnosis and follow-up. Materials & methods: This TM panel was measured approximately 3 monthly. Median follow-up was 29.3 months. Results: At diagnosis, the following TMs were raised: CA15.3 63.2%, CEA 37.3%, CA-125 45.0% and cancer antigen 19.9 17.3%. CA15.3 became raised later in 28/71. Raised TMs were less common in HER2+ tumors. CA-125 was frequently raised in triple negative tumors and was associated with pleural metastases. More raised TMs correlated with more sites of metastases and shorter survival. Conclusion: CEA and CA-125 showed benefit over CA15.3 alone in MBC and all three should be considered in MBC.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0015","citationCount":"11","resultStr":"{\"title\":\"The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer\",\"authors\":\"G. Gaughran, N. Aggarwal, B. Shadbolt, R. Stuart-Harris\",\"doi\":\"10.2217/bmt-2020-0015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Cancer antigen 15.3 (CA15.3) is a commonly used tumor marker (TM) in metastatic breast cancer (MBC) but may not be raised. We assessed CA15.3, carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125) and cancer antigen 19.9 in 193 MBC patients at diagnosis and follow-up. Materials & methods: This TM panel was measured approximately 3 monthly. Median follow-up was 29.3 months. Results: At diagnosis, the following TMs were raised: CA15.3 63.2%, CEA 37.3%, CA-125 45.0% and cancer antigen 19.9 17.3%. CA15.3 became raised later in 28/71. Raised TMs were less common in HER2+ tumors. CA-125 was frequently raised in triple negative tumors and was associated with pleural metastases. More raised TMs correlated with more sites of metastases and shorter survival. Conclusion: CEA and CA-125 showed benefit over CA15.3 alone in MBC and all three should be considered in MBC.\",\"PeriodicalId\":43086,\"journal\":{\"name\":\"Breast Cancer Management\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/bmt-2020-0015\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/bmt-2020-0015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/bmt-2020-0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 11

摘要

背景：癌症抗原15.3（CA15.3）是转移性癌症（MBC）中常用的肿瘤标志物（TM），但可能不升高。我们在193例MBC患者的诊断和随访中评估了CA15.3、癌胚抗原（CEA）、癌症抗原125（CA-125）和癌症抗原19.9。材料和方法：该TM面板大约每3个月进行一次测量。中位随访时间为29.3个月。结果：诊断时，下列TM升高：CA15.3 63.2%，CEA 37.3%，CA-125 45.0%，癌症抗原19.9 17.3%。升高的TMs在HER2+肿瘤中不太常见。CA-125在三阴性肿瘤中经常升高，并与胸膜转移有关。TMs升高越多，转移部位越多，生存期越短。结论：CEA和CA-125在MBC中显示出优于单独CA15.3的益处，在MBC时应考虑这三者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer

Background: Cancer antigen 15.3 (CA15.3) is a commonly used tumor marker (TM) in metastatic breast cancer (MBC) but may not be raised. We assessed CA15.3, carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125) and cancer antigen 19.9 in 193 MBC patients at diagnosis and follow-up. Materials & methods: This TM panel was measured approximately 3 monthly. Median follow-up was 29.3 months. Results: At diagnosis, the following TMs were raised: CA15.3 63.2%, CEA 37.3%, CA-125 45.0% and cancer antigen 19.9 17.3%. CA15.3 became raised later in 28/71. Raised TMs were less common in HER2+ tumors. CA-125 was frequently raised in triple negative tumors and was associated with pleural metastases. More raised TMs correlated with more sites of metastases and shorter survival. Conclusion: CEA and CA-125 showed benefit over CA15.3 alone in MBC and all three should be considered in MBC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.